Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy.
Northern hybridization analyses of the oestrogen-inducible mRNAs pLIV1 and pS2 were compared with oestrogen receptor (ER) immunocytochemistry assessments in 40 untreated primary or early recurrent breast tumours. Significant associations were observed between pLIV1/ER (P < 0.03), pS2/ER (P < 0.001) and pLIV1/pS2 (P < 0.04) status. After disease recurrence, patients were treated with assessable courses of endocrine therapies. Positive pLIV1, pS2 and ER statuses in primary disease were consequently found to be predictive of endocrine responsiveness in the secondary lesions (P < 0.03, P < 0.02, P < 0.005 respectively). However, despite these associations, a number of pLIV1- and/or pS2-positive tumours failed to respond to therapy.
McClelland
R A
RA
Tenovus Cancer Research Centre, University Hospital of Wales, Heath Park, Cardiff, UK.
Manning
D L
DL
Gee
J M
JM
Willsher
P
P
Robertson
J F
JF
Ellis
I O
IO
Blamey
R W
RW
Nicholson
R I
RI
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics*; D004967:Estrogens / Q000235:genetics* / Q000627:therapeutic use; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics*; D011506:Proteins / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D011960:Receptors, Estrogen / Q000032:analysis; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins
D004967:Estrogens; D011506:Proteins; D012333:RNA, Messenger; D011960:Receptors, Estrogen; C051838:TFF1 protein, human; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins